Extended Data Fig. 1: CRISPR–Cas9 screening of RBPs in CML-BC.
a, Differentially expressed genes (DEGs) between CML-CP (n = 42) and CML-BC (n = 28) patients from GSE4170. b, Functional enrichment analysis of DEGs in a; the top eight enriched terms of downregulated genes are labelled. c, Relative expression of genes enriched in four representative GO terms from Fig. 1a. d, Cell proliferation of primary leukemia cells from CML-CP (1#, 2#) and CML-BC (1#, 2#) patients (n = 3). e, Differential expression of all known RBPs between CML-CP (n = 42) and CML-BC (n = 28) patients from GSE4170. f, Western blots showing Cas9 protein levels in Tet-on/Tet-off edited K562 cells post-Dox induction. g, Flow cytometry gating strategy for sorting HPGHigh and HPGLow cell populations following CRISPR/Cas9 screening. h-i, sgRNA distribution of seven known translational regulators between HPGHigh and HPGLow cells (h), or between Day 0 and Day 20 cells post-Dox induction (left of i) with sgRNA abundance in cells on Day 0, 5, 10, 15, 20 was shown (right). j-k, Representative confocal microscopy images and corresponding flow cytometry histograms showing nascent peptides synthesis (j), and cell proliferation (k) in K562 cells following inhibition of each of the seven RBPs (n = 3). l, Normalized expression of PABPC1 in CML patients before (n = 9) and after (n = 9) TKI treatment (GSE33075). Data are shown as the mean ± SEM. P-values were determined by two-way repeated measures ANOVA (d, k), and paired two-tailed Student’s t-test (l), **P < 0.01, ***P < 0.001.